Medterra Supports First-Ever Consumer Clinical CBD Study in the U.S.

“Medterra’s priority will always be to put the the consumer’s health and wellness needs at the forefront. As part of that pledge, a solid understanding and education on the effects of CBD will always be a cornerstone of the brand,” says Medterra CEO Jay Hartenbach. “As excited as we are about the results of the study that show the safety of using CBD, this is just the beginning of consumers’ awareness of how CBD can benefit their everyday life and brings credibility to the whole industry.”

The study emphasized significant findings for the industry:

• The largest multi-branded consumer clinical trial in history – the number of participants allowed for a 90% reliability in results.
• Study was focused on the general population of consumer with 70% of the participants concurrently taking other medications.
• Participants provided real world data based on their consumption of one of a variety of oral CBD products, brands and types of CBD, with no dosing strategy and product recommendations. This real world approach to science revealed no safety issues in the general population across a variety of types of ingestibles from gummies to tinctures.

(This information is primarily sourced from Medterra.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here)